Endometrial and placental CRH as regulators of human embryo implantation
dc.contributor.author | Makrigiannakis, A. | en |
dc.contributor.author | Zoumakis, E. | en |
dc.contributor.author | Kalantaridou, S. | en |
dc.contributor.author | Chrousos, G. | en |
dc.date.accessioned | 2015-11-24T19:19:43Z | |
dc.date.available | 2015-11-24T19:19:43Z | |
dc.identifier.issn | 0165-0378 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21981 | |
dc.rights | Default Licence | - |
dc.subject | Corticotropin-Releasing Hormone/metabolism/*physiology | en |
dc.subject | *Embryo Implantation | en |
dc.subject | Endometrium/*metabolism | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Placenta/*metabolism | en |
dc.subject | Pregnancy | en |
dc.title | Endometrial and placental CRH as regulators of human embryo implantation | en |
heal.abstract | Epithelial cells of the human endometrium and differentiated endometrial stromal cells express the corticotropin-releasing hormone (CRH) gene. CRH is also produced by human placental cytotrophoblast. Endometrial and placental CRH are under the endocrine control of gonadal steroids as well as under autocrine/paracrine regulation by prostanoids and interleukins. Human endometrium, myometrium and placenta express the relevant receptors. Human trophoblast and decidualized endometrial cells also express Fas ligand (FasL), a pro-apoptotic molecule. These findings suggest that intra-uterine CRH may participate in local inflammatory phenomena associated with blastocyst implantation, while FasL may assist with maternal immune tolerance to the semi-allograft embryo. A nonpeptidic CRH receptor type 1 (CRH-R1)-specific antagonist decreased the expression of FasL by human trophoblasts, suggesting that CRH regulates the pro-apoptotic potential of these cells in an auto-paracrine fashion. Invasive trophoblasts promoted apoptosis of activated Fas-expressing human T lymphocytes, an effect potentiated by CRH and inhibited by the CRH antagonist. Female rats treated with the CRH antagonist in the first 6 days of gestation had a dose-dependent decrease of endometrial implantation sites and live embryos as well as markedly diminished endometrial FasL expression. However, embryos of mothers lacking T cells (nude rats) and embryos of syngeneic matings were not rejected when mothers were treated with antalarmin, suggesting that the effect of antalarmin on embryonic implantation is not due to a nonspecific toxicity of this compound but a specific effect on T cells. Our data suggest important physiological roles of endometrial and placental CRH in the regulation of blastocyst implantation and early maternal tolerance. | en |
heal.access | campus | - |
heal.fullTextAvailability | TRUE | - |
heal.identifier.primary | 10.1016/j.jri.2003.11.006 | - |
heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/15288181 | - |
heal.identifier.secondary | http://ac.els-cdn.com/S016503780400035X/1-s2.0-S016503780400035X-main.pdf?_tid=7fc9094e1ae370ba8824a53a77d6590b&acdnat=1333463406_07d1bbc2773b34376e44aa88b6e6dfc3 | - |
heal.journalName | J Reprod Immunol | en |
heal.journalType | peer-reviewed | - |
heal.language | en | - |
heal.publicationDate | 2004 | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
heal.type | journalArticle | - |
heal.type.el | Άρθρο Περιοδικού | el |
heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: